Magenta Therapeutics, Inc.
COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD134+ CELLS

Abstract:

The invention provides methods of preventing and treating graft-versus-host-disease and autoimmune diseases, such as those arising from transplant therapy, by selective depletion of hematopoietic cells through the use of antibody-drug conjugates (ADCs) that specifically bind CD134 or CD278. The compositions and methods described herein can be used to treat a variety of pathologies, including autoimmune diseases, stem cell disorders, and other blood conditions.